Advertisement
CSGP vs PCRX
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CSGP is a Hold and PCRX is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CSGP’s FA Score shows that 1 FA rating(s) are green whilePCRX’s FA Score has 0 green FA rating(s).
- CSGP’s FA Score: 1 green, 4 red.
- PCRX’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CSGP’s TA Score shows that 6 TA indicator(s) are bullish while PCRX’s TA Score has 6 bullish TA indicator(s).
- CSGP’s TA Score: 6 bullish, 3 bearish.
- PCRX’s TA Score: 6 bullish, 4 bearish.
Price Growth
CSGP (@Real Estate Development) experienced а -1.36% price change this week, while PCRX (@Pharmaceuticals: Generic) price change was -0.45% for the same time period.
The average weekly price growth across all stocks in the @Real Estate Development industry was +0.60%. For the same industry, the average monthly price growth was +10.99%, and the average quarterly price growth was +14.56%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -1.53%. For the same industry, the average monthly price growth was +9.50%, and the average quarterly price growth was +84.77%.
Reported Earning Dates
CSGP is expected to report earnings on Oct 28, 2025.
PCRX is expected to report earnings on Oct 30, 2025.
Industries' Descriptions
@Real Estate Development (+0.60% weekly)Activities range from the renovation and re-lease of existing buildings to the purchase of raw land and the sale of developed land or parcels to others. Demand for land development business is driven by GDP growth, employment rates, interest rates, and access to/cost of capital. For individual companies in this industry, proper cost estimation and successful bidding play critical roles in their profitability. Large companies could potentially have greater access to capital, while smaller companies can specialize in a specific geographic area or market niche. CBRE Group, VICI Properties Inc and Brookfield Property Partners L.P. are some of the large companies in this industry.
@Pharmaceuticals: Generic (-1.53% weekly)A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
| CSGP | PCRX | CSGP / PCRX | |
| Capitalization | 37.7B | 1.2B | 3,139% |
| EBITDA | 181M | -1.3M | -13,912% |
| Gain YTD | 24.459 | 41.879 | 58% |
| P/E Ratio | 342.69 | 12.90 | 2,657% |
| Revenue | 2.92B | 706M | 413% |
| Total Cash | 3.94B | 446M | 883% |
| Total Debt | 1.15B | 631M | 183% |
CSGP | PCRX | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 52 | 8 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 97 Overvalued | 57 Fair valued | |
PROFIT vs RISK RATING 1..100 | 87 | 100 | |
SMR RATING 1..100 | 91 | 95 | |
PRICE GROWTH RATING 1..100 | 54 | 41 | |
P/E GROWTH RATING 1..100 | 7 | 100 | |
SEASONALITY SCORE 1..100 | 50 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
PCRX's Valuation (57) in the Pharmaceuticals Other industry is somewhat better than the same rating for CSGP (97) in the Internet Software Or Services industry. This means that PCRX’s stock grew somewhat faster than CSGP’s over the last 12 months.
CSGP's Profit vs Risk Rating (87) in the Internet Software Or Services industry is in the same range as PCRX (100) in the Pharmaceuticals Other industry. This means that CSGP’s stock grew similarly to PCRX’s over the last 12 months.
CSGP's SMR Rating (91) in the Internet Software Or Services industry is in the same range as PCRX (95) in the Pharmaceuticals Other industry. This means that CSGP’s stock grew similarly to PCRX’s over the last 12 months.
PCRX's Price Growth Rating (41) in the Pharmaceuticals Other industry is in the same range as CSGP (54) in the Internet Software Or Services industry. This means that PCRX’s stock grew similarly to CSGP’s over the last 12 months.
CSGP's P/E Growth Rating (7) in the Internet Software Or Services industry is significantly better than the same rating for PCRX (100) in the Pharmaceuticals Other industry. This means that CSGP’s stock grew significantly faster than PCRX’s over the last 12 months.
| CSGP | PCRX | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 50% | 2 days ago 74% |
| Stochastic ODDS (%) | 2 days ago 68% | 2 days ago 79% |
| Momentum ODDS (%) | 2 days ago 76% | 2 days ago 74% |
| MACD ODDS (%) | 2 days ago 66% | 2 days ago 67% |
| TrendWeek ODDS (%) | 2 days ago 60% | 2 days ago 66% |
| TrendMonth ODDS (%) | 2 days ago 60% | 2 days ago 69% |
| Advances ODDS (%) | 9 days ago 63% | 9 days ago 69% |
| Declines ODDS (%) | 3 days ago 59% | 2 days ago 78% |
| BollingerBands ODDS (%) | 2 days ago 53% | 2 days ago 78% |
| Aroon ODDS (%) | 2 days ago 58% | 2 days ago 69% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| SFMRX | 43.21 | 0.33 | +0.77% |
| American Beacon Stephens Mid-Cap Gr R6 | |||
| PRDSX | 45.63 | N/A | N/A |
| T. Rowe Price Integrated US Sm Gr Eq | |||
| TSEGX | 16.32 | N/A | N/A |
| Touchstone Sands Cptl Emerg Mkts Gr Inst | |||
| LIGCX | 11.18 | N/A | N/A |
| Loomis Sayles International Growth C | |||
| ZEMIX | 12.89 | -0.02 | -0.15% |
| American Beacon Ninety One Emr Mkts EqR5 | |||
PCRX and
Correlation & Price change
A.I.dvisor tells us that PCRX and ALKS have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that PCRX and ALKS's prices will move in lockstep.
| Ticker / NAME | Correlation To PCRX | 1D Price Change % | ||
|---|---|---|---|---|
| PCRX | 100% | -1.66% | ||
| ALKS - PCRX | 32% Poorly correlated | -3.60% | ||
| ELAN - PCRX | 32% Poorly correlated | +0.69% | ||
| TEVA - PCRX | 28% Poorly correlated | -1.49% | ||
| COLL - PCRX | 28% Poorly correlated | -0.91% | ||
| ETON - PCRX | 28% Poorly correlated | +2.41% | ||
More | ||||